- POSITIVE
Annual Revenue Hamps Bio Mar-2026 Annual Revenue is Rs 9 Cr which is growth of 29.7% YoY.
- NEGATIVE
Annual Net Profit Hamps Bio Mar-2026 Annual Net Profit is Rs -1 Cr which is growth of -320.0% YoY.
aboutHamps Bio Ltd. (formerly Hamps Bio Private Limited) is an Indian pharmaceutical and fast-moving consumer goods (FMCG) company. The company specializes in the manufacturing of healthcare products and has recently expanded its operational footprint int... Read More
25.500.50(2.00%)
4,000
BSE Volume
BSE 27 Oct, 2026 3:31 PM (IST)
Please subscribe to view forecaster data
Check Before You Buy
VIEW FULL CHECKLISTMedium rank
6Positive7Negative
46.2%Pass in checklist
Check P/E Buy Sell Zone
This stock has negative PE
Hamps Bio Stock Price Analysis
Day Price Range2.0% 1 Day return | 25.5 (LTP) 25.525.5 LowHigh |
|---|---|
Week Price Range2.0% 1 Week return | 25.5 (LTP) 25.525.5 LowHigh |
Month Price Range0.2% 1 Month return | 25.5 (LTP) 22.525.9 LowHigh |
52 Week Price Range-1.9% 1 Year return | 25.5 (LTP) 13.426.6 LowHigh |
Competitors/Peers
Revenue Mix
Annual
Balance Sheet
Ratios
Cash Flow
Documents
Hamps Bio annual results: revenue, profit, P&L, and margins as of Mar 2026 – 11 year history
Nested row level
Base Level
Reporting Type
Standalone
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
| Indicator | Graph | CAGR 3 Yrs | CAGR 5 Yrs | Mar '26 | Mar '25 | Mar '24 | Mar '23 | Mar '22 | Mar '21 | Mar '20 | Mar '19 |
|---|---|---|---|---|---|---|---|---|---|---|---|
16.7% | 17.3% | 8.9 | 6.8 | 6.5 | 5.6 | 5.3 | 4 | 4.6 | 3.9 | ||
Operating Exp. Ann. | 21.4% | 18.5% | 8.4 | 5.9 | 5.3 | 4.7 | 4.7 | 3.6 | 4.1 | 3.4 | |
Operating Profit Ann. | -51.9% | -12.9% | 0.1 | 0.8 | 1.2 | 0.9 | 0.6 | 0.2 | 0.5 | 0.4 | |
OPM Ann. % | -56.9% | -24.2% | 1.24% | 11.28% | 18.11% | 15.51% | 11.52% | 4.97% | 11.34% | 11.42% | |
22.2% | 17.7% | 9.5 | 6.4 | 5.9 | 5.2 | 5.2 | 4.2 | 4.8 | 4.1 | ||
EBITDA Ann. | -23.7% | 0% | 0.4 | 0.9 | 1.2 | 0.9 | 0.6 | 0.4 | 0.5 | 0.5 | |
EBITDA Ann. margin % | -31.7% | -11.5% | 4.99% | 13.50% | 18.51% | 15.63% | 11.59% | 9.17% | 11.34% | 11.62% | |
Interest Ann. | 14.5% | 0% | 0.3 | 0.1 | 0.2 | 0.2 | 0.2 | 0.3 | 0.3 | 0.3 | |
Depr. | 38.7% | 21.7% | 0.8 | 0.4 | 0.4 | 0.3 | 0.3 | 0.3 | 0.4 | 0.4 | |
PBT Ann. | - | - | -0.6 | 0.4 | 0.7 | 0.4 | 0.1 | -0.2 | -0.2 | -0.2 | |
Tax Ann. | - | - | 0 | 0.1 | 0.2 | -0 | -0 | -0 | |||
- | - | -0.7 | 0.3 | 0.5 | 0.4 | 0.1 | -0.2 | -0.1 | -0.2 | ||
Net Profit Ann. | - | - | -0.7 | 0.3 | 0.5 | 0.4 | 0.1 | -0.2 | -0.1 | -0.2 | |
NPM Ann. % | - | - | -7.68% | 4.46% | 7.73% | 6.43% | 2.27% | -5.85% | -3.07% | -4.88% | |
EPS Adj. latest Ann. | - | - | -0.8 | 0.3 | 0.6 | 0.4 | 0.1 | -0.3 | -0.2 | -0.2 |
*All financials are in INR Cr and price data in INR
Add metric to table
Search...
Total Rev. Ann.
1Y CHG
30.9%
2Y CAGR
17%
3Y CAGR
16.7%
5Y CAGR
17.3%
7Y CAGR
12.5%
Total Revenue Annual growth is higher than historical averages.
Operating Exp. Ann.
1Y CHG
42.4%
2Y CAGR
25.9%
3Y CAGR
21.4%
5Y CAGR
18.5%
7Y CAGR
13.8%
Operating Expenses Annual Cr growth is higher than historical averages.
Hamps Bio Technical Analysis
Hamps Bio EMA & SMA
Bullish+8
8 bullish, 0 bearish
Bullish8
Bearish0
| 5 Day | 25.1 |
|---|---|
| 10 Day | 25.0 |
| 12 Day | 24.9 |
| 20 Day | 24.8 |
| 26 Day | 24.7 |
|---|---|
| 50 Day | 24.5 |
| 100 Day | 24.1 |
| 200 Day | 24.8 |
Hamps Bio Delivery And Volume
Daily Avg. Delivery Volume %
27 Oct, 2026100.0%
Week100.0%
Month-
Hamps Bio Active Candlesticks
Short Line Uptrend
Legend
Positive IndicatorNeutral IndicatorNegative Indicator
Hamps Bio Resistance and Support
25.50
Pivot
| First Resistance | 25.5 |
|---|---|
| Second Resistance | 25.5 |
| Third Resistance | 25.5 |
| First Support | 25.5 |
|---|---|
| Second Support | 25.5 |
| Third Support | 25.5 |
| Day RSI | 54.4 |
|---|---|
| Day MACD | 0.2 |
| Day MFI | 63.2 |
| Day MACD Signal Line | 0.1 |
Hamps Bio Beta
| 1 Month | -2.0 |
|---|---|
| 1 Year | -0.2 |
| 3 Month | -2.0 |
|---|---|
| 3 Year | - |
Hamps Bio Price Change Analysis
↑0.2%
Over 1 Month
LowHigh
22.525.9
↓-4.1%
Over 3 Months
LowHigh
20.726
↓0%
Over 6 Months
LowHigh
20.726.6
↓-1.9%
Over 1 Year
LowHigh
13.426.6
Hamps Bio Deals - Insider, Bulk, Block and SAST
| Client Name | Deal Type | Action | Date | Avg. Price | Quantity | Exchange |
|---|---|---|---|---|---|---|
| MUNNI DEVI | Bulk | Sell | 28 Jul 2025 | 59.22 | 22,000 | BSE |
| MULTIPLIER SHARE & STOCK ADVISORS PRIVATE LIMITED | Bulk | Sell | 25 Jul 2025 | 64.61 | 40,000 | BSE |
| MULTIPLIER SHARE & STOCK ADVISORS PRIVATE LIMITED | Bulk | Purchase | 25 Jul 2025 | 64.61 | 40,000 | BSE |
| MANSI SHARE & STOCK ADVISORS PRIVATE LIMITED | Bulk | Sell | 21 Jan 2025 | 63.91 | 22,000 | BSE |
| MANSI SHARE & STOCK ADVISORS PRIVATE LIMITED | Bulk | Sell | 13 Jan 2025 | 63.85 | 38,000 | BSE |
| MANSI SHARE & STOCK ADVISORS PRIVATE LIMITED | Bulk | Sell | 03 Jan 2025 | 81.84 | 72,000 | BSE |
| MANSI SHARE & STOCK ADVISORS PRIVATE LIMITED | Bulk | Purchase | 02 Jan 2025 | 75.50 | 92,000 | BSE |
| ISHAAN TRADEFIN LLP | Bulk | Sell | 02 Jan 2025 | 75.90 | 42,000 | BSE |
| MULTIPLIER SHARE & STOCK ADVISORS PRIVATE LIMITED | Bulk | Sell | 02 Jan 2025 | 75.35 | 84,000 | BSE |
| ISHAAN TRADEFIN LLP | Bulk | Purchase | 01 Jan 2025 | 80.25 | 64,000 | BSE |
Hamps Bio Corporate Actions
Hamps Bio Bonus shares
Hamps Bio bonus history along with announcement, record, ex-bonus dates, and bonus ratios.
#Ex-Date | Bonus Ratio | Record Date |
|---|---|---|
108 Sep 2025 | 1:1 | 09 Sep 2025 |
Hamps Bio Board Meetings
Hamps Bio past and upcoming board meetings.
#Ex-Date | Purpose | Notes |
|---|---|---|
129 May 2026 | Audited Results | - |
214 Nov 2025 | Half Yearly Results | (Revised) |
329 Jul 2025 | Bonus issue | - |
428 May 2025 | Audited Results | - |
Hamps Bio Corporate Filings
Hamps Bio BSE corporate filings and AGM, press releases, insider trading & SAST, results and corporate actions.
| Date | Announcement Title | Details | Links |
|---|---|---|---|
| 14 Oct 2026 | Hamps Bio Ltd - 544312 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 | Certificate under Regulation 74 (5) of SEBI (DP) Regulation, 2018 for the quarter ended 30th September 2026. | |
| 26 Sep 2026 | Hamps Bio Ltd - 544312 - Closure of Trading Window | Closure of Trading Window for declaration of Unaudited Standalone and Consolidated financial results for the half year ending on September 30, 2026. | |
| 11 Sep 2026 | Hamps Bio Ltd - 544312 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report | The voting results along with the Scrutinizer report for 19th AGM is attached herewith. | |
| 09 Sep 2026 | Hamps Bio Ltd - 544312 - Board Meeting Outcome for Board Meeting Outcome | Board Meeting Outcome for Board Meeting held on 9th September, 2026. | |
| 09 Sep 2026 | Hamps Bio Ltd - 544312 - Shareholder Meeting / Postal Ballot-Outcome of AGM | The proceedings of 19th AGM is attached herewith. |
Hamps Bio - Company Profile
Hamps Bio Management Structure
Hamps Bio management structure with salaries, total experience, and qualifications.
Hamps Bio Board of Directors
Hamps Bio Board of directors with salaries, total experience, and qualifications.
Website: www.hampsbio.com
About the company - Business Profile
Hamps Bio Ltd. (formerly Hamps Bio Private Limited) is an Indian pharmaceutical and fast-moving consumer goods (FMCG) company. The company specializes in the manufacturing of healthcare products and has recently expanded its operational footprint into the FMCG sector. Headquartered in Surat, Gujarat, the company operates from its corporate office and manufacturing base in the Bhatpore GIDC area. Hamps Bio Ltd. transitioned to a public limited company and is listed on the BSE Limited (Scrip Code: 544312).
Key Points
- Key Facts:
- Founded Year: 2007 (Incorporated as Hamps Bio Private Limited).
- Headquarters: Plot No C1-B-106, Nr - Mama Bhanja Factory, Bhatpore GIDC, Surat, Gujarat, 394510.
- Stock Listing: Listed on the BSE Mainboard.
- Operations and Resources: The company maintains a manufacturing facility at Bhatpore GIDC, Surat. It has recently invested in significant capacity expansion, particularly for its FMCG division, involving the construction of factory premises and the acquisition of new plant and machinery.
- Ownership: The company was originally a private entity and transitioned to a public limited company to facilitate its listing and capital raising through an initial public offering (IPO).
- Business Model and Expertise: Hamps Bio Ltd. operates a manufacturing-led business model focusing on pharmaceuticals and consumer goods. The company is currently emphasizing growth through vertical expansion into FMCG and brand-building initiatives to enhance market visibility.
- Revenue and Financial Highlights:
- Half-Yearly Performance (Sept 2025): For the half-year ended September 30, 2025, the company reported a gross profit before interest of ₹19.52 lakh, compared to ₹27.42 lakh for the period ending March 31, 2025.
- Cash Flow: Cash and cash equivalents stood at ₹3.14 lakh as of September 30, 2025.
- Strategic Initiatives and Capital Expenditure:
- FMCG Expansion: The company allocated ₹359.00 lakh for the purchase of plant and machinery and construction activities specifically for its FMCG division. As of September 2025, ₹100.15 lakh has been utilized for these activities.
- Brand Visibility: ₹50.00 lakh was earmarked for enhancing brand awareness, with ₹15.88 lakh utilized by mid-FY26.
- Capitalization: The company has capitalized ₹236.07 lakh in wages related to the construction of its new factory premises. Expenditure on product development has also been capitalized, reflecting its transition into a future revenue-generating phase for new products.
- Outlook: The company's current strategy is centered on diversifying its product portfolio into the FMCG segment and scaling its manufacturing capabilities to drive future economic benefits.
References